Proteomic and Metabolomic Analysis of PCK2 in Group 3 Medulloblastoma Cells

Group 3 medulloblastoma accounts for 20–25% of pediatric brain tumor cases. This dataset from figshare contains proteomic and metabolomic data from an analysis of PCK2 knockdown in HD-MB03 and G3MB cells, uploaded by Medha Gayathri J Pai in May 2026. The data is provided in an XLSX file sized 451.7 KB.

Use Cases

• Identify metabolic vulnerabilities for therapeutic targeting based on dysregulated metabolic interactors.
• Analyze changes in ribosomal and RNA processing pathways based on quantitative proteomics data.
• Investigate alterations in phosphocholine, carnitine, and redox-related metabolites based on metabolomic profiling.
• Study the role of PCK2 in metabolic flexibility under nutrient stress in cancer cells.

Strengths

• Data is derived from two independent patient datasets, as mentioned in the description.
• Analysis includes complementary quantitative proteomics and metabolomic profiling.
• Dataset is shared under a CC-BY-NC-4.0 license, permitting non-commercial reuse with attribution.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small at 451.7 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Proteomic analysis using Evosep-Tims TOF and complementary metabolomic profiling following shRNA-mediated knockdown of PCK2.

Freshness

Last updated 2026-05-06 05:14:41; freshness should be verified.